CCG
AKTX

Catalina Capital Group’s Akari Therapeutics AKTX Stock Holding History

Catalina Capital Group’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-328
Closed -$16K – 192
2024
Q4 		$16K Buy
+328
New +$24.7K 0.01% 366

Other funds holding AKTX

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
OFW
Omnia Family Wealth Aventura, Florida $373M AUM 25.3% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Accent Capital Management Centerville, Ohio $206M AUM 29.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return
CPG
Cornerstone Planning Group Fairfield, New Jersey $749M AUM 17.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Catalina Capital Group's AKTX Position: Q1 2025 in Review

Catalina Capital Group sold out of Akari Therapeutics (AKTX) in Q1 2025, closing a stake of 328 shares — an estimated $16K sold.

Catalina Capital Group first reported a position in AKTX in Q4 2024 and held it in 1 quarter. The position peaked at $16K in Q4 2024. 9 funds tracked by Wall St. Rank hold AKTX as of Q1 2025.

  • Catalina Capital Group reported no remaining Akari Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Catalina Capital Group sold 328 Akari Therapeutics shares in Q1 2025, an estimated $16K.
  • Catalina Capital Group first reported a position in Akari Therapeutics in Q4 2024 and held it in 1 quarter.
  • Catalina Capital Group's Akari Therapeutics position peaked at $16K in Q4 2024.
  • 9 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2025.

Based on Catalina Capital Group's 13F filing for Q1 2025, filed 21 Apr 2025.